-

LIBERTY TRIPADVISOR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Liberty TripAdvisor Holdings, Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Liberty TripAdvisor Holdings, Inc. (OTC: LTRPA, LTRPB) to Tripadvisor, Inc. Under the terms of the proposed transaction, (i) shares of Liberty TripAdvisor Series A Common Stock and Series B Common Stock issued and outstanding immediately prior to the effective time will be converted into the right to receive $0.2567 per share in cash (without interest), totaling approximately $20 million in the aggregate; (ii) all of the shares of Liberty TripAdvisor's 8% Series A Cumulative Redeemable Preferred Stock issued and outstanding immediately prior to the effective time will be converted into the right to receive, in the aggregate, $42,471,000 in cash, without interest, and 3,037,959 validly issued, fully paid and non-assessable shares of Tripadvisor common stock; and (iii) Liberty TripAdvisor's 0.50% Exchangeable Senior Debentures (the "Exchangeable Debentures") of approximately $330 million will be repaid in accordance with their terms. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/otc-ltrpa/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
855-768-1857
lewis.kahn@ksfcounsel.com
1100 Poydras St., Suite 960
New Orleans, LA 70163

Kahn Swick & Foti, LLC

OTCQB:LTRPA

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner
855-768-1857
lewis.kahn@ksfcounsel.com
1100 Poydras St., Suite 960
New Orleans, LA 70163

More News From Kahn Swick & Foti, LLC

Talkspace Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Talkspace, Inc. - TALK

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Talkspace, Inc. (NasdaqCM: TALK) to Universal Health Services, Inc. (NYSE: UHS). Under the terms of the proposed transaction, shareholders of Talkspace will receive $5.25 in cash for each share of Talkspace that they own. KSF is seeking to determine whether this consideration and the process that le...

Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Soleno Therapeutics who were adversely affected by alleged securities fraud between March 26, 2025 and November 4, 2025. Follow th...

Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS). On June 23, 2025, Novo Nordisk announced that it was terminating its partnership with Hims & Hers, disclosing that the Company had “failed to adhere to the law which prohibits mass sales of comp...
Back to Newsroom